The 2023 Guidance recommends that, where follow-up screening does not resolve concerns about an order or there is reason to believe a customer may violate United States laws or regulations, providers should not fulfil the order and should contact designated entities within the United States Government, which it identifies as the Department of Commerce and the Federal Bureau of Investigation.
One recorded claim. The claim panel gives its qualification, the source passages with their place in each source, and how it was checked.
What it connects
Screening Framework Guidance for Providers and Users of Synthetic Nucleic Acids → states provision → Recommended action where concerns are not resolved: do not fulfil the order and contact designated government entities
Where it appears
No collection page holds this claim. It is listed with its records in the explorer.